HealthCor Management’s Regeneron Pharmaceuticals REGN Stock Holding History

HealthCor Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-9,570	Closed	-$6.68M	–	72
2022 Q1	$6.68M	Sell	9,570 -18,750	-66%	-$11.9M	0.45%	41
2021 Q4	$17.9M	Buy	+28,320	New	+$17.4M	0.97%	33
2021 Q3	–	Sell	-190,380	Closed	-$106M	–	85
2021 Q2	$106M	Buy	+190,380	New	+$96.5M	4.25%	5
2020 Q4	–	Sell	-190,310	Closed	-$107M	–	66
2020 Q3	$107M	Buy	190,310 +133,760	+237%	+$81.1M	4.26%	10
2020 Q2	$35.3M	Buy	+56,550	New	+$32.1M	1.48%	27
2020 Q1	–	Sell	-372,770	Closed	-$140M	–	58
2019 Q4	$140M	Buy	+372,770	New	+$125M	4.99%	2
2019 Q1	–	Sell	-440,968	Closed	-$165M	–	59
2018 Q4	$165M	Buy	440,968 +40,968	+10%	+$15M	5.15%	4
2018 Q3	$162M	Sell	400,000 -225,000	-36%	-$85.6M	5.36%	4
2018 Q2	$216M	Hold	625,000	–	–	6.85%	2
2018 Q1	$215M	Buy	625,000 +300,000	+92%	+$104M	7.32%	2
2017 Q4	$122M	Buy	+325,000	New	+$132M	3.98%	10

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

HealthCor Management's REGN Position: Q2 2022 in Review

HealthCor Management sold out of Regeneron Pharmaceuticals (REGN) in Q2 2022, closing a stake of 9,570 shares — an estimated $6.68M sold.

HealthCor Management first reported a position in REGN in Q4 2017 and held it in 11 quarters. The position peaked at $216M in Q2 2018. 1,064 funds tracked by Wall St. Rank hold REGN as of Q2 2022.

HealthCor Management reported no remaining Regeneron Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
HealthCor Management sold 9,570 Regeneron Pharmaceuticals shares in Q2 2022, an estimated $6.68M.
HealthCor Management first reported a position in Regeneron Pharmaceuticals in Q4 2017 and held it in 11 quarters.
HealthCor Management's Regeneron Pharmaceuticals position peaked at $216M in Q2 2018.
1,064 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2022.

Based on HealthCor Management's 13F filing for Q2 2022, filed 15 Aug 2022.